 "Alembic Pharma gains on successful USFDA inspection at Baroda facility")
Alembic Pharmaceuticals moved higher by 7% to Rs 645 on BSE in intra-day trade after the successful US drug regulator inspection at the company’s Bioequivalence facility at Baroda in Gujarat. The company said no observations were found after the inspections were carried out by United States Food & Drug Administration (USFDA).
“The USFDA inspected its Bioequivalence facility Baroda (Gujarat, India) from March 6 to March 10, 2017. At the end of the inspection, there were no 483s issued by the USFDA,” Alembic Pharma said in a press release.
A Form 483 has been issued to a company’s management upon conclusion of an inspection if investigators observe any conditions that in their judgement constitute violations of the Food, Drug and Cosmetic (FD&C) Act and related legislation.
At 02:37 pm; the stock was up 5% at Rs 633 on BSE as compared to 0.07% decline in the S&P BSE Sensex. The trading volumes on the counter jumped more than four-fold with a combined 495,547 shares changed hands on BSE and NSE so far.
“The USFDA inspected its Bioequivalence facility Baroda (Gujarat, India) from March 6 to March 10, 2017. At the end of the inspection, there were no 483s issued by the USFDA,” Alembic Pharma said in a press release.
A Form 483 has been issued to a company’s management upon conclusion of an inspection if investigators observe any conditions that in their judgement constitute violations of the Food, Drug and Cosmetic (FD&C) Act and related legislation.
At 02:37 pm; the stock was up 5% at Rs 633 on BSE as compared to 0.07% decline in the S&P BSE Sensex. The trading volumes on the counter jumped more than four-fold with a combined 495,547 shares changed hands on BSE and NSE so far.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%